Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT – Get Free Report) was the target of a large increase in short interest in the month of June. As of June 15th, there was short interest totaling 802,784 shares, an increase of 41,110.7% from the May 31st total of 1,948 shares. Approximately 0.2% of the company’s shares are short sold. Based on an average trading volume of 182,658 shares, the short-interest ratio is currently 4.4 days.
Provectus Biopharmaceuticals Price Performance
Shares of OTCMKTS PVCT opened at $0.07 on Friday. The firm has a fifty day moving average of $0.06 and a 200-day moving average of $0.06. Provectus Biopharmaceuticals has a 52-week low of $0.04 and a 52-week high of $0.10.
About Provectus Biopharmaceuticals
Provectus Biopharmaceuticals, Inc is a U.S.-based clinical-stage biopharmaceutical company focused on the development and commercialization of immuno-oncology and tumor ablation therapies. Headquartered in Knoxville, Tennessee, the company’s lead investigational product is PV-10, a proprietary formulation of Rose Bengal disodium for intralesional injection. PV-10 is designed to selectively ablate tumor cells while stimulating a systemic immune response against cancerous lesions.
PV-10 has been evaluated in multiple clinical trials across a range of solid tumors, with key studies conducted in melanoma, hepatocellular carcinoma and other refractory cancers.
Recommended Stories
- Five stocks we like better than Provectus Biopharmaceuticals
- MDA Space Targets US Defense Market With $620M Acquisition
- Carnival’s Second Quarter: Is the Stock Still Complicated?
- Domino’s Stock Slides to 52-Week Low as Investors Digest CEO Change
- Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal
Receive News & Ratings for Provectus Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Provectus Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
